MedTrace Logo

Cereboost (American Ginseng Extract) and Brain Function

NCT07255755 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-12-09

No results posted yet for this study

Summary

The study will assess the immediate, short-term benefits of a single dose of a supplement containing 200mg of Panax quinquefolius (American Ginseng) on cognition (brain function) in healthy young adults.

To understand the effect this product may have, the participants will complete a series of questionnaires and cognitive tests (tests of memory and brain function) at set intervals across a 6-hour period. Blood samples will also be collected to assess the impact of the study product on the participants.

Conditions

  • Attention
  • Cognition

Interventions

DIETARY_SUPPLEMENT

American Ginseng extract

Cereboost TM capsules delivering 200 mg of Panax quinquefolius extract standardised for ginsenosides (10-12%)

DIETARY_SUPPLEMENT

Placebo product

Placebo capsules, identical in appearance to active treatment, but only containing maltodextrin

Sponsors & Collaborators

  • Givaudan France Naturals

    collaborator INDUSTRY

  • Atlantia Food Clinical Trials

    collaborator INDUSTRY

  • University of East Anglia

    lead OTHER

Principal Investigators

  • David Vauzour, PhD · University of East Anglia

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07255755 on ClinicalTrials.gov